Glaucoma The word "glaucoma" comes from the Ancient Greek γλαύκωμα, a derivative of γλαυκóς, which commonly described the color of eyes which were not dark (i.e. blue, green, light gray). Eyes described as γλαυκóς due to disease might have had a gray cataract in the Hippocratic era, or, in the early Common Era, the greenish pupillary hue sometimes seen in angle-closure glaucoma. Rho kinase inhibitors, such as ripasudil, work by inhibition of the actin cytoskeleton, resulting in the morphological changes in the trabecular meshwork and increased aqueous outflow. More compounds in this class are being investigated in phase 2 and phase
Glaucoma valve drainage, such as iStent, CyPass, or Hydrus. A Cochrane Review of various aqueous shunts and modifications found that the Baerveldt implant may result in lower IOP than the Ahmed implant, but it was unclear if the difference in IOP reduction was clinically significant. The review suggests that practitioners should operate with the devices that they are most comfortable with, and have the most experience using. The glaucoma valve implant is indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy) or in cases where conventional drainage surgery is unlikely to succeed. Common situations